Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study.

William F. Keane, Zhongxin Zhang, Paulette A. Lyle, Mark E. Cooper, Dick de Zeeuw, Jean Pierre Grunfeld, James P. Lash, Janet B. McGill, William E. Mitch, Giuseppe Remuzzi, Shahnaz Shahinfar, Steven M. Snapinn, Robert Toto, Barry M. Brenner

Research output: Contribution to journalArticleResearchpeer-review

165 Citations (Scopus)


Diabetic nephropathy is the most important cause of ESRD. The aim of this study was to develop a risk score from risk predictors for ESRD, with and without death, in the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study and to compare ability of the ESRD risk score and its components to predict ESRD. The risk score was developed from coefficients of independent risk factors from multivariate analysis of baseline variables and equals (1.96 x log [urinary albumin:creatinine ratio]) - (0.78 serum albumin [g/dl]) + (1.28 x serum creatinine [mg/dl]) - (0.11 x hemoglobin [g/dl]). It was robust with respect to severity of nephropathy, gender, race, and treatment group. The risk score for ESRD or death was comparable. The four risk predictors for progression of kidney disease were independent of therapy. For combined treatment groups, the hazard ratio between the fourth and first quartiles of the ESRD risk score was 49.0, as compared with the corresponding hazard ratios for each component: 14.7 for urinary albumin:creatinine ratio, 9.2 for serum creatinine, 5.5 for hemoglobin, and 10.2 for serum albumin. The RENAAL risk scores for ESRD with or without death emphasize the importance of identification of level of albuminuria, serum albumin, serum creatinine, and hemoglobin to predict development of ESRD in patients with type 2 diabetes and nephropathy. Although albuminuria is a strong risk factor for ESRD, the contribution of serum albumin, serum creatinine, and hemoglobin level further enhances prediction of ESRD. Future trials with a similar patient population and outcomes measures should consider adjusting analyses for baseline risk factors.

Original languageEnglish
Pages (from-to)761-767
Number of pages7
JournalClinical Journal of the American Society of Nephrology
Issue number4
Publication statusPublished - Jul 2006
Externally publishedYes

Cite this